NT indicates not tested; CML, chronic myeloid leukemia; MegL, megakaryoblastic leukemia; EL, erythroleukemia; APL, acute promyelocytic leukemia; AMoL, acute monocytic leukemia; AML, acute myeloblastic leukemia; and ALL, acute lymphoblastic leukemia.

Protein levels of the small Jab1 complex were assessed by immunoblotting: -, no detectable signal even after a long exposure; +, detection of a very weak signal (less than one fifth that in MEG-01 cells); + +, detection of a strong signal (equal to that in MEG-01 cells; + + +, detection of a very strong signal (more than twice that in MEG-01 cells). The intensity of the immunoblotting signals was analyzed with a densitograph and the average of 2 experiments used

Relative decreased levels of the small Jab1 complex on STI571 treatment: →, no change; ↓, decrease in more than 40% and up to 80% of pretreated cells; ↓ ↓, decrease in more than 80% of pretreated cells

Relative increased levels of p27 on STI571 treatment: →, no change; ↑, increase in more than 30% and up to 70% of pretreated cells; ↑ ↑, increase in more than 70% of pretreated cells

KCL-22 cells are known to be relatively resistant to STI571

NALM1 cells are derived from lymphoid crisis of CML